IGF1R and B-cell chronic lymphocytic leukemia: In a mouse model of idelalisib resistance, resistant CLL cells exhibited increased mitogen-actived protein kinase (MAPK) signalling through enhanced expression of insulin-like growth factor 1 receptor (IGF1R), which could be abrogated using a small molecule inhibitor, lisitinib.